Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-022924
Filing Date
2025-08-25
Accepted
2025-08-25 16:31:42
Documents
1
Period of Report
2025-08-24

Document Format Files

Seq Description Document Type Size
1 form3-08252025_080839.html 3  
1 form3-08252025_080839.xml 3 3166
  Complete submission text file 0001415889-25-022924.txt   4795
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 4A FEUERSTEIN STREET TEL-AVIV L3 6900328
Business Address
Mamlok Gilad (Reporting) CIK: 0001975896 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33357 | Film No.: 251251375